AzTrials
AzTrials

Infertility, FemaleACONCT04482751

The Relationship Between Serum AMH Dynamics and Early or Normal Ovarian Response to Corifollitropin Alfa

An observational study of Infertility, Female, run by Azienda Ospedaliero-Universitaria di Modena at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The objective of this study is to evaluate the trend of serum AMH during IVF (in vitro fertilization) cycles, in particular the possible relationship between the dynamics of AMH and the early or normal response to therapies for controlled ovarian stimulation with corifollitropin alfa. Read more about this study

Who is it for?
Ages 18 to 46 years, women only
Conditions the study is for
Infertility, Female
What is being tested?
Corifollitropin alfa
How many people
80 participants
Where
1 siteItaly
Study dates
1 Aug 2020to 30 Sep 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 46 years
  • Women only
  • No healthy volunteers
  • Adult

Study population: Infertile patients

Who may be able to join

  • basal serum FSH concentration below 20 UI/L
  • age between 18 and 46 years
  • body weight > 60 kg
  • use of corifollitrofin alpha for ovarian stimulation.

Who cannot join

  • contraindications to IVF
  • irregular menstrual cycles

Trial locations and contacts

1 site in 1 country.

Antonio La Marca contact

+390594224671

antlamarca@libero.it

Antonio La Marca contact

3384795303

antlamarca@libero.it

Italy1 site, 1 recruiting
  • Policlinico di Modena

    Modena, Modena - MO, 41123

    Antonio La Marca, 3384795303, antlamarca@libero.it

    Recruiting

Other trials in Italy

About this study

Official title: An Observational Single Center Study to Identify the Relationship Between Serum AMH Dynamics and Early or Normal Ovarian Response to Corifollitropin Alfa (ACO Study)

The objective of this study is to evaluate the trend of serum AMH during IVF (in vitro fertilization) cycles, in particular the possible relationship between the dynamics of AMH and the early or normal response to therapies for controlled ovarian stimulation with corifollitropin alfa. The secondary objective is to study the association between the number of follicles equal to or greater than 17 mm on the eighth day of ovarian stimulation and the decline in AMH, and to assess the predictability of the need to add additional therapies after the first week of stimulation ovarian.

Read the detailed description

The study is observational and it is monocentric, and it will involve 80 patients. Patients' data, extrapolated from the medical records of the Department of Reproductive Medicine in the Policlinico Hospital in Modena, will be collected in an internal database for analysis. The inclusion criteria for the population included in the study will be: 1) basal serum FSH concentration below 20 UI/L; 2) age between 18 and 46 years; 3) body weight > 60 kg; 4) use of corifollitrofin alpha for ovarian stimulation. The following parameters will be evaluated: the age of the patients, their weight, their body mass index (BMI), duration of infertility, cycle characteristics; basal (day 2) AMH, AFC measurement, basal estradiol, basal progesterone, basal FSH, basal LH, and those same values on day 5 and day 8 of ovarian stimulation; follicles ≥ 17 mm on day 8, type of gonadothropin further added, days of stimulation with the further gonadothropin and its units per day, AMH on trigger day and the number of oocytes retrieved. The confidentiality of the informations will be guaranteed by anonymized data analysis. All the data are commonly recorded in our clinical practice.

The observed period will be of 12 months. The date of conclusion of the study, after favorable opinion of the Ethics Committee and the authorization of the Company Management, is scheduled for June 2021.

To guarantee the consent and the information of the patients involved in the study, the Information Sheet and the relative Consent Form are attached. We consider appropriate to inform the General Physician of the enlisted patients about the study: the Information Letter for the General Physician is therefore attached.

Variables/Time Points of Interest

The variables which will be recorded on cycle day 2 of a spontaneous menstruation (stimulation day 1 with Corifollitropin alfa) are: woman's age (years), weight (kg), body-mass-index (kg/m2), duration of infertility (months), cycle length (in days, by patient recall), cycle regularity (yes/no; deviation of > 5 days from two consecutive cycles is considered an irregular cycle), total number of antral follicles (2-10 mm) in both ovaries (AFC) measured by a transvaginal scan and serum AMH (ng/ml), oestradiol, progesterone, FSH and LH.

Patients will return every two days to the clinic for a transvaginal ultrasound from stimulation day 5 up to and including the day of hCG. Serum hormone concentrations (FSH, LH, oestradiol, progesterone and AMH) will be measured on stimulation days 5 and 8 and on the day of hCG.

All hormones reported above will be measured in the central lab of the ospital as per routine practice. Remaining serum will be used for the AMH assay. The measurement of the AMH will ber profrmed in the ObGyn University research Lab.

Being tested
Corifollitropin alfa
Medical subject headings
Infertility, Female

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Corifollitropin alfaDrug

    Also called no other interventions

    AMH will be measured during ovarian stimulation with corifollitropin alfa

Study groups in NCT04482751
Study groupRoleWhat they receive
Infertile womenthe group consists of 80 infertile patients undergoing IVF
Receives: Drug: Corifollitropin alfa

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes in serum Antimullerian Hormone (AMH) levels during ovarian stimulation

    Serum concentrations of AMH will be measured during ovarian stimulation with corifollitropin alfa.

    Measured: AMH will be measured at day 2, day 5, day 8 and the last day (usually day 11) of ovarian stimulation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jul 2020
  2. Study start1 Aug 2020
  3. Primary completion30 Jun 2023 (estimated)
  4. Study completion30 Sep 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04482751
Sponsor's protocol ID
184/2020
Acronym
ACO
Status last verified
Feb 2023
First submitted
3 Jul 2020
Last updated
8 Feb 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Infertility, Female, run by Azienda Ospedaliero-Universitaria di Modena at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 8 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Antonio La Marca (+390594224671, antlamarca@libero.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes in serum Antimullerian Hormone (AMH) levels during ovarian stimulation (time frame: AMH will be measured at day 2, day 5, day 8 and the last day (usually day 11) of ovarian stimulation). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Feb 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in